NasdaqGS:LIVNMedical Equipment
What LivaNova (LIVN)'s KeyBanc Upgrade and Medtech Reassessment Means For Shareholders
In late January 2026, KeyBanc Capital Markets upgraded its rating on LivaNova PLC to Overweight, citing sustainable underlying trends in the Medical Technology segment and a reduced valuation premium.
This shift, alongside Goldman Sachs maintaining coverage with a Neutral stance, highlights increasing institutional focus on how LivaNova fits into the broader medtech landscape.
Next, we’ll explore how KeyBanc’s upgraded view on LivaNova’s position within Medical Technology could influence...